Along with rising sales, GLP-1s are a major focus for R&D teams. Major pharma companies are developing new versions of the ...

When people feel dismissed, confused or misaligned with their healthcare experience, they often quietly disengage long before ...

CSL will pay $355M upfront to Alentis plus up to $1.2B milestones, while financing Phase II completion and Phase III in AAV-RPGN and Phase II programs in FSGS and PSC. Lixudebart targets claudin-1, ...

Two FDA approvals, six platform deals, a European alarm, a Novo listing debate, and a China mega-deal — this week's biggest ...

Termination of the SMARCA2 program reflects insufficient antitumor activity despite acceptable tolerability, highlighting the gap between mechanistic rationale and clinical benefit in synthetic lethal ...

Real-world data from Novo's Octane study show patients who switched from injectable GLP-1 therapy to oral semaglutide lost an ...

Four long-acting antibodies will be jointly advanced, targeting IL-13, IL-4, IL-4Rα, and IL-4xIL-13, extending type 2 ...

Pharming CEO Fabrice Chouraqui has stepped down amid strategic disagreements with the board, with chief commercial officer Leverne Marsh and chief financial officer Kenneth Lynard now serving as ...

In today's Pharmaceutical Executive Daily, Foghorn Therapeutics and Eli Lilly discontinue development of FHD-909, their oral ...

Dr. Liang previously worked at Novo Nordisk, where he lead global clinical development and regulatory submission for ...

FDA broadened Camzyos use to symptomatic oHCM in adults and pediatric patients ≥30 kg, representing the first adolescent ...

Merck has acquired exclusive global rights to SciBrunch's preclinical KRAS G12D inhibitor SPR2015. Merck entered into an ...